Entera Bio (NASDAQ:ENTX) Issues Quarterly Earnings Results

Key Points

• Entera Bio reported an earnings per share of ($0.06), surpassing analysts' estimates of ($0.11) by $0.05.
• The company's stock increased by 1.1% to $1.82, with a current market capitalization of approximately $82.72 million.
• Entera Bio is focused on developing orally delivered peptide and protein therapeutics, with product candidates in clinical trials for hypoparathyroidism and osteoporosis.

Entera Bio (NASDAQ:ENTX - Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.05, Zacks reports. Entera Bio had a negative return on equity of 77.75% and a negative net margin of 4,525.11%.

Entera Bio Stock Performance

ENTX traded up $0.03 during trading on Thursday, hitting $1.97. The stock had a trading volume of 89,820 shares, compared to its average volume of 290,754. The company has a market capitalization of $89.95 million, a PE ratio of -7.58 and a beta of 1.52. Entera Bio has a twelve month low of $1.50 and a twelve month high of $2.79. The stock has a 50 day simple moving average of $1.95 and a two-hundred day simple moving average of $1.99.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upgraded Entera Bio to a "strong-buy" rating in a research note on Monday.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.